Zhejiang Jinhua Conba Bio-Pharm is an API manufacturer based in China. It holds 7 active US drug master files across a filed portfolio of 7 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 28 April 2025 as VAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| China, China | 3003663281 |
| Molecule | Regulators | Docs |
|---|---|---|
| Acetylcysteine | US FDA | 1 |
| Aripiprazole | US FDA | 1 |
| Azithromycin | US FDA | 1 |
| Dabigatran Etexilate | US FDA | 1 |
| Omeprazole | US FDA | 1 |
| Rivaroxaban | US FDA | 1 |
| Tazobactam | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | None | 1 |
Choose your molecules and target markets. Zhejiang Jinhua Conba Bio-Pharm comes back tiered against every other supplier able to file there.
Start for free